Complete Recovery of Visual Acuity As the Main Goal of Treatment in Patients with Dysthyroid Optic Neuropathy
Overview
Authors
Affiliations
Introduction: To evaluate the effectiveness of methylprednisolone (MP) and surgical treatment in achieving complete reversal of dysthyroid optic neuropathy (DON) and predictive factors of this therapy.
Material And Methods: The group consisted of 10 patients (18 eyes) with DON. The diagnosis of DON was based on at least two criteria from the following: (i) deterioration of visual acuity (VA< 1.0), (ii) loss of colour vision, (iii) optic disc swelling, and/or (iv) signs of DON in magnetic resonance imaging (presence of apical crowding and/or optic nerve stretching). A complete recovery of DON was defined as the normalisation of VA (VA = 1.0), normal colour vision, and reversal of optic disc swelling. A significant improvement was defined as improvement of VA of at least 0.2. The consecutive steps of treatment of DON consisted of: (i) first-line treatment - intravenous MP pulse therapy (3 × 1 g); (ii) second-line treatment - endoscopic intranasal orbital decompression of medial wall; (iii) additional treatment - additional MP therapy and/or surgical decompression.
Results: A significant improvement in VA could be achieved in the majority of patients; a complete recovery was noted in 22.2%, 33.3%, and 66.7% of eyes after first-line, second-line, and additional treatment, respectively. Positive predictive factors were: younger age (p = 0.049), shorter duration of DON (p = 0.035), and a higher Graves' orbitopathy clinical activity score (p = 0.035).
Conclusions: By using combination therapy (intravenous MP pulse therapy and surgical decompression), a complete recovery can be achieved in the majority of patients with DON.
Sawicka-Gutaj N, Gruszczynski D, Zawalna N, Nijakowski K, Skiba A, Pochylski M Pharmacol Rep. 2024; 76(1):185-194.
PMID: 38273183 PMC: 10830746. DOI: 10.1007/s43440-023-00567-0.
Chung C, Ko T, Wei Y, Liao S Indian J Ophthalmol. 2024; 72(Suppl 2):S233-S239.
PMID: 38271419 PMC: 11624645. DOI: 10.4103/IJO.IJO_863_23.
Roles of four targets in the pathogenesis of graves' orbitopathy.
Ren Z, Zhang H, Yu H, Zhu X, Lin J Heliyon. 2023; 9(9):e19250.
PMID: 37810014 PMC: 10558314. DOI: 10.1016/j.heliyon.2023.e19250.
Sarnat-Kucharczyk M, Pojda-Wilczek D, Swierkot M, Kulawik G, Mrukwa-Kominek E Doc Ophthalmol. 2023; 148(1):47-55.
PMID: 37775645 PMC: 10879228. DOI: 10.1007/s10633-023-09955-6.
Dysthyroid optic neuropathy: emerging treatment strategies.
Pelewicz-Sowa M, Miskiewicz P J Endocrinol Invest. 2023; 46(7):1305-1316.
PMID: 36802028 PMC: 10261203. DOI: 10.1007/s40618-023-02036-0.